Systematic Financial Management LP Has $32.16 Million Holdings in AngioDynamics, Inc. $ANGO

Systematic Financial Management LP lowered its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 2.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,504,864 shares of the medical instruments supplier’s stock after selling 65,642 shares during the period. Systematic Financial Management LP owned approximately 6.08% of AngioDynamics worth $32,162,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ANGO. Goldman Sachs Group Inc. lifted its position in shares of AngioDynamics by 9.6% in the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock worth $2,434,000 after buying an additional 22,658 shares during the last quarter. Jane Street Group LLC lifted its position in shares of AngioDynamics by 267.1% in the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock worth $439,000 after buying an additional 34,054 shares during the last quarter. Legal & General Group Plc lifted its position in shares of AngioDynamics by 279.5% in the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 9,098 shares during the last quarter. Rhumbline Advisers lifted its position in shares of AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after buying an additional 2,510 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in shares of AngioDynamics by 15.8% in the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock worth $960,000 after buying an additional 13,217 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $11.92 on Friday. AngioDynamics, Inc. has a twelve month low of $8.36 and a twelve month high of $13.99. The stock has a market capitalization of $492.53 million, a PE ratio of -15.89 and a beta of 0.37. The stock has a 50-day simple moving average of $10.83 and a 200 day simple moving average of $11.42.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The business had revenue of $78.42 million during the quarter, compared to analysts’ expectations of $76.77 million. As a group, equities research analysts forecast that AngioDynamics, Inc. will post -0.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Canaccord Genuity Group reduced their price target on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.67.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.